Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease |
| |
| Authors: | Tricia Nicholson Alistair McGuire Ruairidh Milne |
| |
| Institution: | (1) Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK;(2) Economics Department, City University, London, UK |
| |
| Abstract: | Background Low molecular weight heparins hold several advantages over unfractionated heparin including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use in unstable coronary artery disease (unstable stable angina and non-Q wave myocardial infarction). In these patients, two large randomised controlled trials and their meta-analysis showed small benefits for enoxaparin over unfractionated heparin at 30–43 days and potentially at one year. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
